Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC

Gray J. E. , Villegas A., Daniel D., Vicente D., Murakami S., Hui R., ...Daha Fazla

JOURNAL OF THORACIC ONCOLOGY, cilt.15, ss.288-293, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 15 Konu: 2
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.jtho.2019.10.002
  • Dergi Adı: JOURNAL OF THORACIC ONCOLOGY
  • Sayfa Sayıları: ss.288-293

Özet

Introduction: In the phase 3 PACIFIC study of patients with unresectable stage III NSCLC without progression after chemoradiotherapy, durvalumab demonstrated significant improvements versus placebo in the primary end points of progression-free survival (hazard ratio [HR] = 0.52, 95% confidence interval [CI]: 0.42-65, p < 0.0001) and overall survival (OS) (HR = 0.68, 95% CI: 0.53-0.87, p = 0.00251), with manageable safety and no detrimental effect on patient-reported outcomes. Here, we report 3-year OS rates for all patients randomized in the PACIFIC study.